Acute Pancreatitis Market Size

Acute Pancreatitis Market Analysis

The acute pancreatitis market studied is expected to register an estimated CAGR of 5.07% over the forecast period.

COVID impacted the growth of the acute pancreatitis market owing to the suspension of diagnosis and treatment services as well as the shutdown of hospitals due to the lockdown measures imposed by the government. For instance, according to an article published in the International Journal of Molecular Science in January 2022, it was observed that some SARS-CoV-2 inpatients developed acute pancreatitis as a result of the virus directly infecting the tissue or from systemic multiple organ dysfunction syndromes (MODS), which was accompanied by increased amylase and lipase levels. Additionally, a literature review published in Frontiers in Medicine in January 2022 showed that 7% of patients with severe COVID-19 had imaging signs consistent with pancreatitis, whereas 17% of them had pancreatic damage with high serum lipase and amylase levels. Thus, the high risk of pancreatitis among COVID-19 patients impacted the demand for acute pancreatitis treatment during the forecast period. However, with the resumed services and increased hospital visits, the market is expected to grow over the forecast period.

Factors such as the increasing incidence of gallstones and obesity and ongoing research and development activities for the diseases are boosting market growth.

The rising burden of gallstones and obesity among the population raises the risk of developing acute pancreatitis, which in turn is expected to increase the demand for effective drugs and devices to reduce pain and treat the condition, hence propelling market growth. For instance, according to an article published in the NLM in September 2021, it has been observed that the incidence of acute pancreatitis is increasing over time, especially in western countries. As per an article published in the Gastrointestinal Journal, in April 2022, the annual incidence of acute pancreatitis will range from 4.9 to 35 per 100,000 people in the United States.

Additionally, smoking, high alcohol consumption, and obesity in the population are found to be the most prevalent risk factors for gallstones and acute pancreatitis, respectively. This is anticipated to increase market growth over the forecast period. For instance, as per the 2022 statistics published by the World Population, Naru (61%) has the highest number of obese populations, followed by Palau (55.30%), the United States (36.20%), and Egypt (32%). As per the same source, Vietnam (2.10%) has the lowest number of obese people. The high number of obese populations raises the level of hypertriglyceridemia in the body as well as increases gallstones. This is anticipated to increase the risk of developing acute pancreatitis, hence bolstering market growth.

Furthermore, as per an article published in the NLM in May 2022, it has been observed that chronic alcohol use is the second most common cause of acute pancreatitis (AP) after gallstones, accounting for 17% to 25% of cases of the condition globally. Also, as per the data published by the Australian Bureau of Statistics, in March 2022, one in four Australians aged 18 and older exceeded the Australian Adult Alcohol Guideline in 2020-21 (25.8%). Thus, the increasing prevalence of alcohol consumption is expected to increase market growth by increasing the prevalence of acute pancreatitis.

Moreover, the rising research and development activities of the companies are also contributing to market growth. For instance, in April 2021, Lamassu Pharma developed a new treatment, RABI-767, a novel small molecule lipase inhibitor, to treat acute pancreatitis.

Therefore, owing to the aforementioned factors, the studied market is expected to grow over the forecast period. However, the poor reimbursement policies and high cost of treatment, as well as the stringent regulatory requirements for drug and device approvals, are expected to impede the growth of the acute pancreatitis market over the forecast period.